Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 90 clinical trials
Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer

with cabozantinib and atezolizumab, has demonstrated safety for the treatment of other cancers and has shown promise in preclinical studies utilizing patient derived pancreas organoids. In this study

metastatic pancreatic cancer
  • 0 views
  • 27 Dec, 2021
  • 1 location
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

This research study will assess whether cabozantinib, nivolumab and ipilimumab in combination are safe and effective in slowing down the growth of kidney cancer(renal cell carcinoma or RCC) that

ipilimumab
nivolumab
nephrectomy
cabozantinib
kidney cancer
  • 0 views
  • 04 Oct, 2022
  • 3 locations
hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"

Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm

  • 0 views
  • 04 Mar, 2021
  • 1 location
Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma

This is an open-label, single-center, Phase II trial designed to estimate in terms of PFS the efficacy of cabozantinib, given as second- or third- line treatment in HCC patients that progress on

neutrophil count
radiofrequency ablation
hepatitis
antiviral drugs
antiviral therapy
  • 0 views
  • 24 Jan, 2021
  • 1 location
Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

In this phase II advanced melanoma study, all patients will receive treatment with nivolumab/ipilimumab plus cabozantinib for a 12 week induction period followed by nivolumab plus cabozantinib

advanced melanoma
nivolumab
ipilimumab
measurable disease
  • 8 views
  • 11 May, 2022
  • 3 locations
Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

This is a phase I clinical trial assessing the safety and recommended phase II dose of cabozantinib in combination with trifluridine/tipiracil (TAS102) in patients with metastatic colorectal

carcinoma
  • 0 views
  • 09 Oct, 2021
  • 1 location
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas (PEMBROCABOSARC)

Phase II trial with three independent strata to independently assess the effects of the association of pembrolizumab and cabozantinib in advanced sarcomas.

undifferentiated pleomorphic sarcoma
systemic therapy
cancer chemotherapy
measurable disease
carcinoma
  • 0 views
  • 04 Oct, 2022
  • 1 location
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The hypothesis

  • 0 views
  • 21 Apr, 2022
  • 1 location
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs

The purpose of the CTO-IUSCCC-0752 study is to investigate the use of Cabozantinib for patients with incurable, refractory germ cell tumors. Patients will be treated until evidence of disease

alpha fetoprotein
human chorionic gonadotropin
teratoma
neutrophil count
seminoma
  • 1 views
  • 08 Jul, 2022
  • 1 location
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

This phase II trial studies how well pembrolizumab and cabozantinib in treating patients with head and neck squamous cell cancer that has come back or spread to other places in the body and

cavity
potassium
systemic therapy
absolute neutrophil count
human papillomavirus
  • 46 views
  • 12 Mar, 2022
  • 2 locations